Novartis AG: PharmaVitae Report
Datamonitor, November 2011, Pages: 103
This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Novartis's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for Novartis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Novartis's performance against key rivals in the prescription pharmaceutical sector
- Assess Novartis's industry-leading diversification strategy, bolstered most recently via acquisition of the ophthalmology specialist Alcon
- Analyze the internal growth drivers which are expected to position Novartis as the industry's leading prescription pharmaceutical player by 2016
Executive Summary
Key findings
Novartis prescription pharma sales outlook
Novartis financial outlook
SWOT analysis
[Missing title]
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Novartis is forecast to deliver the strongest organic growth within the Big Pharma peer set over 2010–
A diversified prescription pharma offering is integral to sales growth performance
Exposure to generic competition will blunt branded pharmaceutical sales growth
Sandoz poised to exploit diverse segments of global generics market
Geographic expansion
Technology investment, therapeutic expansion, and biosimilars
Further diversification to be driven by Alcon acquisition
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Push into generics market
Movement into vaccines/diagnostics
Alcon deal demonstrates further diversification
Recent M&A in branded prescription segment
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–
Product analysis
Product analysis, 2004–
Product analysis, 2010–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–
Core analysis, 2010–
Expiry analysis, 2010–
Generics analysis, 2010–
Launch/core/expiry configuration, 2010–
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–
Operating costs and profit analysis
Operating costs and profit analysis, 2004–
Operating cost ratio and profit margin analysis, 2004–
Operating cost ratio and profit margin analysis, 2010–
Operating costs and profit analysis, 2010–
PRODUCT ANALYSIS
Overview
Gilenya
Afinitor
Tasigna
QMF
QVA
Diovan/Co-Diovan
Glivec/Gleevec
Zometa (including Aclasta/Reclast)
Femara
Sandostatin
APPENDIX
References
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
